Quantum News
Sign InSign Up
Back to News
research

uniQure N.V. (QURE) Q4 2025 Earnings Call Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
uniQure reported Q4 2025 earnings with a narrower-than-expected loss of $0.56 per share, beating estimates by $0.37, though revenue of $5.53M missed projections by $182K. CEO Matthew Kapusta highlighted progress in gene therapy pipelines, emphasizing advancements in Huntington’s disease and Fabry disease programs as key 2026 priorities during the March 2 call. Chief Medical Officer Walid Abi-Saab outlined regulatory milestones, including planned FDA submissions for AMT-191 (Fabry disease) and updated Phase I/II data for AMT-130 (Huntington’s) in mid-2026. CFO Christian Klemt noted $320M in cash reserves, projecting runway into 2027, despite a 5.95% year-over-year revenue decline attributed to lower collaboration income. Analysts pressed on commercialization timelines, with leadership reaffirming partnerships to accelerate global market access for its gene therapies.
AI Audio Summary
0:00 / 0:00
Click to play
Untitled design (38).png
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts158.75K FollowersFollow5ShareSaveCommentsQ4: 2026-03-02 Earnings SummaryInsightsTranscript InsightsPlay CallPlay CallEPS of -$0.56 beats by $0.37 | Revenue of $5.53M (5.95% Y/Y) misses by $182.33K uniQure N.V. (QURE) Q4 2025 Earnings Call March 2, 2026 8:00 AM EST Company Participants Chiara Russo - Senior Director of Investor RelationsMatthew Kapusta - CEO & Executive DirectorWalid Abi-Saab - Chief Medical OfficerKylie O'Keefe - Chief Customer & Strategy OfficerChristian Klemt - CFO, Principal Financial Officer & GM of Amsterdam Site Conference Call Participants Joseph Schwartz - Leerink Partners LLC, Research DivisionJohn Peyton Bohnsack - TD Cowen, Research DivisionSuzanne van Voorthuizen - Kempen & Co. N.V., Research DivisionLuca Issi - RBC Capital Markets, Research DivisionSalveen Richter - Goldman Sachs Group, Inc., Research DivisionUy Ear - Mizuho Securities USA LLC, Research DivisionLuis Santos - H.C. Wainwright & Co, LLC, Research DivisionKristen Kluska - Cantor Fitzgerald & Co., Research DivisionGuofang Li - Wolfe Research, LLC Presentation Operator Thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the uniQure Fourth Quarter and Year-End 2025 Earnings Call. [Operator Instructions] I would now like to turn the call over to Chiara Russo, Senior Director of Investor Relations. Please go ahead. Chiara RussoSenior Director of Investor Relations Good morning. and thank you for joining us for uniQure's year-end 2025 earnings call. Earlier this morning, uniQure released its financial results for the fourth quarter and year-end of 2025, and our press release is available on the Investors and Media section of our website at uniqure.com. Our 10-K was also filed with the SEC earlier this morning. Joining me on the call this morning are Matt Kapusta, Chief Executive Officer; Dr. Walid Abi-Saab, Chief Medical Officer; Kylie O'Keefe, Chief Customer and Strategy Officer; and Christian Klemt, Chief Financial Officer. After our formal remarks, we'll open up the call for Q&A. Before we begin, please note that we will be

Read Original

Tags

quantum-finance

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.